Business
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide a
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio","displaySize":"","headline":null,"caption":"Entera Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":237,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PKeefwE624EAwJoXBY3bXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515","width":237,"height":138}},"lazy":false},{"type":"text","content":"Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling","length":107,"tagName":"p"},{"type":"text","content":"Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 ","length":93,"tagName":"p"},{"type":"text","content":"Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants","length":87,"tagName":"p"},{"type":"text","content":"Strategic Partnership Discussions Advancing Across Pipeline","length":59,"tagName":"p"},{"type":"text","content":"JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced its expected corporate milestones for the first quarter of 2026.","length":284,"tagName":"p"},{"type":"text","content":"“We expect to achieve three important goals during Q1 2026 to drive value for patients with osteoporosis and hypoparathyroidism. We would like to thank the investigators from around the world who participated in our Phase 3 feasibility study, and the patients who are reaching out since our FDA alignment for EB613 in July 2025. We hear you and remain steadfast in our commitment to advance this important program back into clinic. As a Company, we continue to invest and innovate in therapeutic spaces that have been ignored, require urgent attention and practical treatments and plan to also accelerate our hypoparathyroidism program this year. This is the second women-centric underserved condition where we believe our oral peptides can make a real difference," said Miranda Toledano, CEO of Entera.","length":820,"tagNam...